Mekinist (trametinib) — Medica
Fallopian Tube Cancer
Initial criteria
- Patient has recurrent disease
- Patient meets ONE of the following: i) The medication is used for low-grade serous carcinoma; OR ii) Patient has BRAF V600 mutation-positive disease AND the medication will be taken in combination with Tafinlar (dabrafenib)
Approval duration
1 year